DSGN

In the past six months, Design Therapeutics' stock has been impacted by several events, including a RESTORE-FA clinical development update and Q2 2026 financial results in August 2026, initiation of patient dosing for DT-818 in Myotonic Dystrophy Type-1 in June 2026, and positive four-week intravenous data from the RESTORE-FA trial of DT-216P2 in May 2026, which demonstrated clinical improvements and comprehensive biomarker activity in Friedreich ataxia, showing a 6.4-point improvement in mFARS. The company also reported Q1 2026 financial results in April 2026 and Q4 and full-year 2025 financial results in March 2026, along with business updates on its GeneTAC® clinical portfolio. The stock's 52-week low was $5.27-$5.28, and its 52-week high was $17.19-$17.25. As of September 2026, the stock has seen a significant increase of 145.19% over the past year.